Print this page
Friday, 29 April 2022 07:49

Anticoagulation news items. Week commencing 25th April 2022

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism

Journal of Thrombosis and Haemastasis
Study (n=8246) found reduced bleeding with rivaroxaban (R) vs enoxaparin/VKA in pts without comedication but similar risk in pts with ≥4 comedications. CYP3A4 +/- P-gp inhibitors were associated with doubled bleeding risk vs no use, with no difference between R and enoxaparin/VKA.

 

Thromboembolic Events in JAK inhibitors: A Pharmacovigilance Study From 2012 to 2021 Based on FAERS

British Journal of Clinical Pharmacology
Study covered 8 types of JAKinibs already on the market, and found several safety signals with embolic and thrombotic events linked to use of ruxolitinib, tofacitinib IR and XR, baricitinib, upadacitinib and filgotinib. Some of these signals require further confirmatory data.

 

Does co-prescribing non-steroidal anti-inflammatory drugs and oral anticoagulants increase the risk of major bleeding, stroke and systemic embolism?

British Journal of Clinical Pharmacology
In this cohort study (n=6354) it was shown that concomitant use of NSAIDs with oral anticoagulants (OAC) increased the risk of GI bleeding (HR 3.0, 95%CI: 1.6 to 5.6) and reduced the protective effect against stroke (HR 2.7: 1.5 to 5.1) compared to OAC alone.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services